Product Review: Ibrance

In this review:

This review discusses the use of palbociclib (Ibrance®), a highly selective inhibitor of cyclindependent kinase (CDK) 4 and 6, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. PALOMA was the first clinical programme to investigate how a CDK 4/6 inhibitor, palbociclib, could benefit women with HR-positive/HER2-negative advanced breast cancer and is now supported by real-world evidence. Together with randomised controlled trial data, the real-world evidence for palbociclib can be used to both understand and help support improvement of HR-positive/HER2-
negative advanced breast cancer patient outcomes. This publication has been commissioned by Pfizer New Zealand Limited.

Please login below to download this issue (PDF)